CL2018002023A1 - Uso de moduladores de receptores de gabaa para el tratamiento de picor. - Google Patents

Uso de moduladores de receptores de gabaa para el tratamiento de picor.

Info

Publication number
CL2018002023A1
CL2018002023A1 CL2018002023A CL2018002023A CL2018002023A1 CL 2018002023 A1 CL2018002023 A1 CL 2018002023A1 CL 2018002023 A CL2018002023 A CL 2018002023A CL 2018002023 A CL2018002023 A CL 2018002023A CL 2018002023 A1 CL2018002023 A1 CL 2018002023A1
Authority
CL
Chile
Prior art keywords
treatment
itching
receptor modulators
gabaa receptor
general formula
Prior art date
Application number
CL2018002023A
Other languages
English (en)
Inventor
Hanns Ulrich Zeilhofer
William Ralvenius
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of CL2018002023A1 publication Critical patent/CL2018002023A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE PROPORCIONA UN COMPUESTO PARA SU USO EN EL TRATAMIENTO DE PICOR, EN EL QUE EL COMPUESTO COMPRENDE LA FÓRMULA GENERAL (1A), FÓRMULA GENERAL (1B) O FÓRMULA GENERAL (1C). LOS COMPUESTOS DE LA INVENCIÓN SON MODULADORES DE RECEPTORES DE GABAA a2 Y/O a3 ALOSTÉRICOS POSITIVOS.
CL2018002023A 2016-01-27 2018-07-26 Uso de moduladores de receptores de gabaa para el tratamiento de picor. CL2018002023A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16153035 2016-01-27
EP16178824 2016-07-11

Publications (1)

Publication Number Publication Date
CL2018002023A1 true CL2018002023A1 (es) 2019-02-01

Family

ID=57890845

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002023A CL2018002023A1 (es) 2016-01-27 2018-07-26 Uso de moduladores de receptores de gabaa para el tratamiento de picor.

Country Status (14)

Country Link
US (3) US10786513B2 (es)
EP (1) EP3407886A1 (es)
JP (2) JP7115746B2 (es)
KR (1) KR102482200B1 (es)
CN (1) CN108697694B (es)
AU (1) AU2017213154B2 (es)
BR (1) BR112018015386A2 (es)
CA (2) CA3012791C (es)
CL (1) CL2018002023A1 (es)
IL (1) IL260775B (es)
MX (1) MX388862B (es)
SG (1) SG11201806393QA (es)
UA (1) UA125463C2 (es)
WO (1) WO2017129801A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017213154B2 (en) 2016-01-27 2023-02-02 Universität Zürich Use of GABAA receptor modulators for treatment of itch
WO2019204446A1 (en) * 2018-04-18 2019-10-24 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds, methods of making, and uses thereof
EP3796907A4 (en) * 2018-05-22 2021-11-03 Neurocycle Therapeutics, Inc. GABAA POSITIVE ALLOSTERIC MODULATING COMPOUNDS FOR THE TREATMENT OF PRURITUS AND / OR DERMATITIS
US11396510B2 (en) 2018-09-13 2022-07-26 Saniona A/S GABAA receptor ligand
US20220152037A1 (en) * 2019-03-18 2022-05-19 Neurocycle Therapeutic, Inc. Use of gabaa receptor modulators for treatment of pain
CN110004118B (zh) * 2019-03-29 2023-03-28 中国科学院武汉物理与数学研究所 用于辅助重组狂犬病毒在神经细胞高效逆向跨单级突触的rAAV病毒的包装方法及其应用
BR112022007648A2 (pt) * 2019-10-23 2022-10-11 Neurocycle Therapeutics Inc Tratamento de condições epilépticas com moduladores do receptor gabaa
US12233070B2 (en) * 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024526A (en) 1911-07-25 1912-04-30 George R Schweikert Chair.
ATE236904T1 (de) 1996-07-25 2003-04-15 Merck Sharp & Dohme Substituierte triazolo-pyridazin-derivate als liganden von gaba-rezeptoren
FR2767692B1 (fr) 1997-09-01 2000-03-03 Oreal Utilisation d'une substance agoniste d'un recepteur associe a un canal chlore ou potassique dans le traitement des peaux sensibles
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB9903119D0 (en) * 1999-02-11 1999-04-07 Merck Sharp & Dohme Therapeutic agents
CA2427779A1 (en) 2000-11-10 2002-05-16 Merck Sharp & Dohme Limited Imidazo-triazine derivatives as ligands for gaba receptors
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
KR20080060286A (ko) 2002-03-28 2008-07-01 위시스 테크놀로지 파운데이션, 인크. 진정 및 운동실조 효과가 감소된 항불안제
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
JP2004170323A (ja) * 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
JPWO2005030773A1 (ja) * 2003-09-26 2006-12-07 大日本住友製薬株式会社 新規ピラゾロピリミジン誘導体
WO2005108401A1 (en) * 2004-04-29 2005-11-17 Dov Pharmaceutical, Inc. 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
RU2450004C2 (ru) 2006-08-04 2012-05-10 Мерц Фарма Гмбх Унд Ко. Кгаа Замещенные пиразолопиримидины, способ их получения и их применение в качестве лекарственного средства
KR101532256B1 (ko) 2006-11-22 2015-06-29 인사이트 코포레이션 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
EP2188284A2 (en) * 2007-08-14 2010-05-26 Novartis Ag Tricyclic heterocyclic compounds as gaba a modulators
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
CA2759547A1 (en) 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
WO2011011712A1 (en) 2009-07-24 2011-01-27 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
KR101477156B1 (ko) * 2010-08-25 2014-12-29 (주)네오팜 신규한 헤테로고리 화합물 및 이를 이용한 염증성 질환 치료용 조성물
US20130331394A1 (en) 2012-06-11 2013-12-12 The Mclean Hospital Corporation Treating schizophrenia
HUE042591T2 (hu) * 2013-02-19 2019-07-29 Ono Pharmaceutical Co TRK-gátló vegyület
WO2015072853A1 (en) * 2013-11-13 2015-05-21 Rjg Developments B.V. Treatment of herpes virus infection outbreaks
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
CA2979701C (en) 2015-03-20 2023-01-03 Uwm Research Foundation, Inc. Oxazole substituted benzimidazodiazepines and their uses as gabaergic ligands
AU2017213154B2 (en) 2016-01-27 2023-02-02 Universität Zürich Use of GABAA receptor modulators for treatment of itch

Also Published As

Publication number Publication date
SG11201806393QA (en) 2018-08-30
RU2018128905A (ru) 2020-02-27
MX2018009252A (es) 2019-01-21
CN108697694B (zh) 2022-12-09
EP3407886A1 (en) 2018-12-05
JP2022088620A (ja) 2022-06-14
US12433898B2 (en) 2025-10-07
US20250268912A1 (en) 2025-08-28
IL260775B (en) 2021-09-30
KR20180118623A (ko) 2018-10-31
US20210100814A1 (en) 2021-04-08
US10786513B2 (en) 2020-09-29
CA3222584A1 (en) 2017-08-03
CA3012791A1 (en) 2017-08-03
BR112018015386A2 (pt) 2019-03-19
US11529359B2 (en) 2022-12-20
AU2017213154A1 (en) 2018-08-16
CA3012791C (en) 2024-01-23
AU2017213154B2 (en) 2023-02-02
JP7115746B2 (ja) 2022-08-09
JP2019507736A (ja) 2019-03-22
UA125463C2 (uk) 2022-03-16
WO2017129801A1 (en) 2017-08-03
US20190134057A1 (en) 2019-05-09
MX388862B (es) 2025-03-20
KR102482200B1 (ko) 2022-12-27
RU2018128905A3 (es) 2020-03-24
CN108697694A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
CL2018002023A1 (es) Uso de moduladores de receptores de gabaa para el tratamiento de picor.
AR134579A2 (es) Proceso para la preparación de un compuesto de diariltiohidantoína
AR132627A2 (es) Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
CR20190071A (es) Compuestos, composiciones y métodos para el tratamiento de enfermedades
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
MX392605B (es) Compuestos, composiciones y metodos para el tratamiento de enfermedades.
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
ECSP18044917A (es) Compuestos inhibidores de la quinasa de unión a tank
DOP2017000289A (es) Moduladores de receptor nuclear
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CR20160419A (es) Nuevos compuestos biciclicos
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CR20170484A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2018003085A1 (es) Síntesis de indazoles
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
DK3805220T3 (da) Polycykliske carbamoylpyridon-derivater til behandling af hiv
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
CL2017000505A1 (es) Proceso para la elaboración de derivados de pirimidin sulfamida.(div. sol. 2008-2016).
MX2018008771A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
CL2018003121A1 (es) Inhibidores del potenciador del homólogo zeste 2.
MX2018008772A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.